Last update Nov. 24, 2021
Very Low Risk
"The vaccine (COVID-19) can be offered to a breastfeeding woman who is part of a group recommended for vaccination (e.g. health workers); discontinuing breastfeeding after vaccination is currently not recommended". (WHO 2021/01/25)
Several types of vaccines are currently in development against COVID-19, among those in production there are (WHO 2021/01/26):
Currently breastfeeding women have been excluded from all pre-marketing clinical trials. (Palacios 2020, Costantine 2020, CDC 2020/12/15, ABM 2020/12/14)
There were no significant differences between nursing mothers and non-lactating women in terms of side effects and the rate of antibodies generated after the COVID-19 vaccine. (Falsaperla 2021/10, Perl 2021/04, Gray 2021/03)
COVID vaccines cause rare and minimal adverse effects in breastfeeding or nursing infants.(Falsaperla 2021/10, Low 2021/10, McLaurin 2021/06) Infants of vaccinated mothers did not present any serious problems attributable to vaccination. (Low 2021/10, Perl 2021/04, Gray 2021/03) Few cases of transient increase or decrease in milk production, change to a blue-green color of the milk and irritability-insomnia have been published in the infant, more frequent after the second dose of vaccine. (Bertrand 2021/09)
As expected (Baird 2021/02, InfantRisk 2020/12, ABM 2020/12) as after vaccination against other viruses, in the milk of lactating mothers vaccinated against COVID-19 appear antibodies (IgA and IgG especially) generated by the vaccine, which would protect the infant from COVID-19. (Falsaperla 2021/10, Valcarce 2021/08, Collier 2021/05, Perl 2021/04, Kelly 2021/03, Gray 2021/03) The longer breastfeeding (> 23 months) there is a higher rate of IgG and IgA antibodies in breast milk among lactating women vaccinated with the COVID19 vaccine. (Ramírez 2021/08)
It is highly improbable that any of the components that are part of the vaccines produced against COVID-19 could be excreted through human breastmilk, and even in this could happen, they would all be digested in the gastrointestinal tract of the breastfeeding child (InfantRisk 2020/12) After vaccination, no COVID-19 vaccine-related messenger RNA has been detected in breast milk.(Golan 2021/10)
Neither of the types of vaccines currently in development against COVID-19 contain live viruses within their components and therefore cannot provoke the disease or cause any alterations to the genetic material of their host. (CDC 2020/12/18 y 2020/12/13) Except for three live attenuated virus vaccines (small pox, yellow fever and oral polio-Sabin) that are known to rarely bring about negative effects on breastfeeding children, all vaccines are to be regarded as safe for use during lactation and therefore can be prescribed to breastfeeding women. (CDC 2020/02)
Breastfeeding women are not considered to be a high-risk group for COVID-19, specially since they tend to be young and usually healthy and therefore until now there are no specific reasons that would warrant the use of the vaccine in this group. Several Health institutions, medical societies and also expert consensus have suggested that the vaccine should be prescribed for breastfeeding women if they would also belong to a high-risk group such as healthcare workers or people afflicted by a chronic disease or condition known to be a risk factor. (Mayo 2021/03, Davanzo 2021/02, Saus 2021/02, Chervenak 2021/02, WHO 2021/01, Sax 2021, IHAN 2021, AELAMA 2021, NHS 2021, HIFN 2020, MS España 2020/12, ACOG 2020/12, CDC 2020/12 y 2020/12)
Vaccinating against COVID-19 should not be an impediment to begin lactation nor a cause for its interruption. (Davanzo 2021/02, Chervenak 2021/02, ACOG 2020/12) At the end of the year 2020; AstraZeneca, Moderna and Pfizer withdrew from their respective drug leaflets the previous recommendation of not administering their vaccines to lactating mothers. (Moderna 2021, AstraZeneca 2021, Pfizer 2020)
As it may happen with other vaccinations, after the COVID-19 vaccination, palpable axillary lymph nodes may appear on the same side of the vaccine injection. A clinical follow-up of the nodes would be enough to rule out a presumed malignancy at the level of the breast. Costly and unnecessary complementary examinations should be avoided.(Low 2021/10, Edmonds 2021, Mehta 2021) This is a transitory side effect that usually does not disrupt the continuity of breastfeeding.
Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.